This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KRBP Kiromic BioPharma (KRBP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Kiromic BioPharma Stock (NASDAQ:KRBP) Get Kiromic BioPharma alerts:Sign Up Key Stats Today's Range$0.16▼$0.1650-Day Range$0.21▼$1.6652-Week Range$0.16▼$3.32VolumeN/AAverage Volume11,347 shsMarket Capitalization$251.52 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Read More Receive KRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRBP Stock News HeadlinesKRBPQ Kiromic BioPharma, Inc.May 30, 2025 | seekingalpha.comHouston-based Kiromic BioPharma finds buyer for assets after filing Chapter 7April 7, 2025 | bizjournals.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 29 at 1:00 AM | Profits Run (Ad)Houston cancer treatment co. files for bankruptcy months after settling SEC chargesMarch 21, 2025 | bizjournals.comKiromic BioPharma Files for Chapter 7 BankruptcyMarch 21, 2025 | marketwatch.comKiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free SurvivalFebruary 18, 2025 | finance.yahoo.comKiromic says Deltacel-01 trial patient reaches progression-free survivalFebruary 18, 2025 | markets.businessinsider.comKiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01January 21, 2025 | uk.finance.yahoo.comSee More Headlines KRBP Stock Analysis - Frequently Asked Questions How were Kiromic BioPharma's earnings last quarter? Kiromic BioPharma, Inc. (NASDAQ:KRBP) posted its quarterly earnings data on Friday, November, 8th. The company reported ($0.65) earnings per share (EPS) for the quarter. When did Kiromic BioPharma's stock split? Shares of Kiromic BioPharma reverse split on Monday, March 13th 2023.The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Kiromic BioPharma IPO? Kiromic BioPharma (KRBP) raised $16 million in an initial public offering on Friday, October 16th 2020. The company issued 1,200,000 shares at $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Paulson Investment Company was co-manager. What other stocks do shareholders of Kiromic BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiromic BioPharma investors own include KLX Energy Services (KLXE), Brainstorm Cell Therapeutics (BCLI), NGL Energy Partners (NGL), TherapeuticsMD (TXMD) and Achilles Therapeutics (ACHL). Company Calendar Last Earnings11/08/2024Today5/29/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRBP CIK1792581 Webwww.kiromic.com Phone832-968-4888FaxN/AEmployees60Year Founded2012Profitability EPS (Trailing Twelve Months)($3.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.90 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-277.46% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($8.29) per share Price / Book-0.02Miscellaneous Outstanding Shares1,571,000Free Float1,217,000Market Cap$251.52 thousand OptionableNot Optionable Beta1.66 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:KRBP) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiromic BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiromic BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
